Five Prime claims a big win in topline data for their comeback gastric cancer drug as shares skyrocket
Five Prime Therapeutics $FPRX has kept a relatively low profile following a flop in pancreatic cancer in late 2017. But the biotech declared victory in gastric cancer Tuesday after releasing topline data from a 155-person Phase II study.
The South San Francisco-based company announced that its experimental drug bemarituzumab, in combination with chemotherapy, met all of its pre-specified efficacy endpoints. Five Prime was aiming for a new pathway in the fibroblast growth factor receptor 2b, which is overexpressed in about 30% of all HER2 negative gastric cancers, the company says.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.